How much is the device itself?
The Solarc storefront pages checked August 13, 2026 showed a configured-price range beginning around $945 for the cited handheld family and reaching about $6,225 for a cited multi-panel configuration, before shipping or later changes. These are dated first-party storefront observations, not a market-wide typical price, a quote for a reader, or independent evidence of value. Solarc publishes storefront prices for the product families cited here. Phothera describes insurance help, delivery, discounted cash pricing, and payment options, but the reviewed page does not publish complete model-level prices or terms. A public price or its absence does not establish market share, sales mix, motive, final cost, or comparative value. Check current model-level pricing in the device guide and get a written quote before you pay or file for reimbursement.
Ultraviolet lamps for dermatologic disorders are FDA-classified as Class II devices, and 21 CFR 801.109 defines the federal labeling framework for prescription devices. Those records do not prove the status of a marketplace listing or decide whether a particular device, seller, or transaction complies.
What keeps costing money after the box arrives?
Fluorescent NB-UVB lamps are consumables: output falls with use, and manufacturers sell replacement lamps for exactly this reason. Solarc runs a dedicated replacement-bulb store. Phothera routes replacement lamps (which themselves require a prescription) plus exact-model eyewear and acrylic parts through its support channel. Ask the manufacturer for the current lamp price and expected lamp life for your exact model before you buy. Over years of ownership, that recurring cost plus electricity is easy to leave out of your math.
Can HSA or FSA money pay for this?
Maybe. Prescription durable medical equipment may be an eligible medical expense. Eligibility is decided by current IRS rules and by your account administrator, and I can’t decide it for you. Verify with your administrator before you spend, and ask what documentation it wants, such as the prescription and an itemized receipt.
What do the medications alongside it cost in cash?
If you’re also filling prescriptions, that line can be bigger than the device itself. Opzelura’s documented manufacturer list cost was $2,094 per tube (checked August 16, 2026). Its copay card can drop that to as little as $0 for eligible commercially insured patients, with maximums and exclusions. There is no card if you’re on government insurance or paying cash. Generic Protopic (tacrolimus) ran about $35–$39 per 30 g tube with a coupon, and many generic topical corticosteroids were $10–$40. A coupon isn’t insurance and usually doesn’t count toward your deductible or out-of-pocket maximum.
See the full medication price and assistance table, with checked dates
| Medication | Generic available? | Typical cost path | Assistance | Checked |
|---|---|---|---|---|
| Opzelura (ruxolitinib) | No FDA-approved generic was found in the current record. | Documented manufacturer list cost (WAC) checked August 16, 2026: $2,094 for one tube. WAC is not the amount everyone pays; the pharmacy and insurer must quote the actual amount. | Eligible people with commercial insurance may pay as little as $0 per tube under the current manufacturer offer, with maximums and exclusions. Government-funded coverage and cash-pay patients cannot use that card. A separate assistance program may help some uninsured, underinsured, or Medicare Part D patients. | Evidence · 3 sources
|
| Protopic (tacrolimus) | FDA-approved generic versions are available. | Vendor estimate checked August 16, 2026: about $35–$39 with a coupon for one 30 g tube of generic tacrolimus, depending on strength and pharmacy. Retail averages were much higher; compare the exact prescription and location. | Generic coverage is plan-specific, and off-label vitiligo use can still trigger an authorization or quantity limit. A discount coupon is not insurance and usually does not count toward the plan deductible or out-of-pocket maximum. | Evidence · 2 sources
|
| Elidel (pimecrolimus) | An FDA-approved generic is available. | Vendor estimate checked August 16, 2026: about $70–$80 with a coupon for one 30 g tube of generic pimecrolimus 1%. Pharmacy and location differences were substantial. | Generic coverage is plan-specific, and off-label vitiligo use can still trigger an authorization or quantity limit. No current Elidel-specific manufacturer savings program was verified. | Evidence · 2 sources
|
| Topical corticosteroids (many generic products) | Many generic creams and ointments are available; ingredients and potency are not interchangeable. | Vendor estimates checked August 16, 2026: many commonly used generic topical corticosteroids were roughly $10–$40 per tube with a cash discount. The ingredient, formulation, quantity, pharmacy, and location change the price. | Many are formulary medicines, but plan rules and quantity limits vary. Ask the pharmacy to compare the insurance amount with the live cash-discount amount for the exact product. | Evidence · 2 sources
|
| Dovonex (calcipotriene; former brand name) | Generic calcipotriene products are available; Dovonex is a familiar former brand name. | Vendor estimate checked August 16, 2026: roughly $55–$80 with a coupon for a common 60 g calcipotriene 0.005% cream prescription. Prices vary, and this is not a standard vitiligo treatment cost. | Coverage is plan-specific. Its FDA-approved indication is psoriasis, not vitiligo, so off-label use can affect coverage or authorization. | Evidence · 1 source
|
Is paying cash ever the wrong move?
Practical tip - not financial or benefits advice
A useful cash-versus-insurance comparison
Before paying cash, keeping the plan’s written decision and building a two-column comparison - cash today versus a documented deductible and coinsurance - can clarify the trade-off. It also helps to separate a device’s useful life from a single plan-year deductible. Appeal rights, assistance requirements, prices, and plan terms all vary, so treat this as a method, not a number to match.
Questions to bring to the plan, program, tax professional, or supplier (7)
Questions for the plan, program, tax professional, or supplier
A quoted price is not the whole cost. These are the questions that find the rest of it.
- Which costs continue after delivery?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What documentation does my account require?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What will I owe if assistance ends?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What will I owe if the claim is not paid?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would I owe after a return?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What happens if the device breaks?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would I owe if I stop using it?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- U.S. Department of Labor, Employee Benefits Security AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that participants in ERISA-covered plans receive or may request important plan documents, including the summary plan description, and that written requests can matter.
What it does not support
It does not apply identically to every coverage regime, interpret a specific plan, establish coverage for phototherapy, or provide legal advice.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- HealthCare.gov, U.S. Centers for Medicare & Medicaid ServicesRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a general US individual and group health-plan distinction between internal appeal and eligible external review, and the need to use the denial notice for instructions.
What it does not support
Rights, deadlines, urgent pathways and external-review availability vary by plan and jurisdiction, so this source does not supply a universal deadline or guarantee review.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Centers for Medicare & Medicaid ServicesRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current Medicare context that DMEPOS orders use standardized elements and that supporting documentation is beneficiary-specific.
What it does not support
It does not establish that a home phototherapy device is covered, identify a code, apply to commercial plans, or replace the current plan and supplier requirements.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Internal Revenue ServiceRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports general federal tax context that qualifying medical expenses may be eligible for certain tax-favored health accounts and that reimbursement and deduction cannot be duplicated.
What it does not support
It does not determine whether a specific phototherapy purchase qualifies, interpret a person’s plan document, or provide tax advice.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Phothera PhototherapyManufacturer document · Manufacturer, tier 4Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports Phothera’s current first-party description of benefit checks, prior-authorization help, delivery, insured-patient assistance, discounted cash pricing and payment options for its devices.
What it does not support
It does not advertise a consumer rental, publish complete prices or terms, guarantee eligibility or coverage, or independently establish product value.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the current FDA classification of ultraviolet lamps for dermatologic disorders as Class II medical devices.
What it does not support
It does not validate a marketplace listing, establish that a particular unit is genuine or cleared, determine a lawful transfer pathway, or show that a used device remains serviceable.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Electronic Code of Federal RegulationsRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the federal prescription-device labeling and distribution framework.
What it does not support
It does not decide whether a specific private transaction is lawful, replace state law, authorize a seller, transfer a prescription, or establish that a used unit is safe or supported.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Solarc Systems Inc.Manufacturer document · Manufacturer, tier 4Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Solarc manufactures and sells the products whose first-party storefront prices are recorded.
What this source supports
Supports only the dated public price and option range displayed for the cited SolRx handheld family.
What it does not support
It does not establish a final cart total, shipping, future price, insurance payment, clinical fit, market-wide price, or independent product value.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Solarc Systems Inc.Manufacturer document · Manufacturer, tier 4Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Solarc manufactures and sells the products whose first-party storefront prices are recorded.
What this source supports
Supports only the dated public price and configuration range displayed for cited SolRx panel families.
What it does not support
It does not establish a final cart total, shipping, installation, future price, insurance payment, clinical fit, market-wide price, or independent product value.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.